Wednesday, July 8, 2026

pharma · Advanced Solid Tumor · Hepatocellular Carcinoma

Coherus Oncology

Coherus Oncology clinical programs — 25 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, US HQ
2010 Founded
212 Employees
NMPA registrant Type
Company details
Status
Public
HQ
333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, US
Founded
2010
Employees
212
Programs
25
Drugs
11
Patents
73
Intelligence · Clinical Programs

Coherus Oncology projects

25 ClinicalTrials.gov programs sponsored by Coherus Oncology.

Coherus Oncology has 25 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CHS-0214

    Coherus Oncology

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial
  2. CHS-1420

    Coherus Oncology

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial
  3. Etanercept

    Coherus Oncology

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial
  4. Etanercept

    Coherus Oncology

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial
  5. Casdozokitug

    Coherus Oncology

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial
  6. Dupilumab

    Coherus Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial
  7. NY-ESO-1 Peptide vaccine

    Coherus Oncology

    Ovarian Cancer Stage IV

    phase 2 mab active

    1 trial
  8. Nadunolimab

    Coherus Oncology

    Metastatic Microsatellite Stable Colorectal Carcinoma

    phase 2 small molecule active

    1 trial
  9. SRF388

    Coherus Oncology

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial
  10. STC-15 in combination with toripalimab

    Coherus Oncology

    Solid Tumor

    phase 2 other active

    1 trial
  11. Toripalimab

    Coherus Oncology

    Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

    phase 2 small molecule active

    1 trial
  12. Toripalimab

    Coherus Oncology

    Localized Colon Carcinoma

    phase 2 small molecule active

    1 trial
  13. Toripalimab

    Coherus Oncology

    Sinonasal Cancer

    phase 2 small molecule active

    1 trial
  14. Toripalimab + Chemotherapy

    Coherus Oncology

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial
  15. Toripalimab-tpzi

    Coherus Oncology

    Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  16. CHS-006 (anti-TIGIT)

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial
  17. CHS-1000

    Coherus Oncology

    Advanced or Metastatic Solid Tumors

    phase 1 mab active

    1 trial
  18. CHS-114

    Coherus Oncology

    Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial
  19. CHS-114

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial
  20. CHS-1701

    Coherus Oncology

    Immunity, Humoral

    phase 1 small molecule completed

    1 trial
  21. CHS-1701

    Coherus Oncology

    Healthy

    phase 1 small molecule completed

    1 trial
  22. CHS-1701

    Coherus Oncology

    Bioequivalence

    phase 1 small molecule completed

    1 trial
  23. CHS-388

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial
  24. SRF617

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial
  25. Toripalimab

    Coherus Oncology

    Nasopharyngeal Cancer Recurrent

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Coherus Oncology have?

25 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.